anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for stereoselectively reducing an unsaturated alkyl ketone substituent attached to a fused ring base, and to provide a method for producing squalamine or other useful aminosterol compounds.  &lt;P&gt;SOLUTION: In this method, the unsaturated alkyl ketone is reacted with a chiral oxazaborolidine reagent. This reaction stereoselectively reduces the unsaturated alkyl ketone to an unsaturated alkyl alcohol. The unsaturated alkyl alcohol can be further reduced, if desired, to produce a saturated alkyl alcohol. The fused ring base can be, for example, a steroid ring base or a base of a vitamin D analog, and can be used with an alkeneone substituent (e.g., a 22-ene-24-one substituent) or an alkyneone substituent (e.g., a 22-yne-24-one substituent) on a steroid ring base to make squalamine or other useful aminosterol compounds and intermediates for producing aminosterol compounds.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
PURPOSE: A therapeutic agent for treating dermatitis using thinner for diluting lacquer is provided to relieve itch and to reduce recurrence rate of atopy without side effects. CONSTITUTION: A therapeutic agent for treating dermatitis contains thinner for diluting lacquer. The thinner is used for treating atopic dermatitis. The lacquer thinner is also used in treating skin inflammation, red spot, and athlete&#39;s foot. The therapeutic agent is applied on the skin three to four times. The thinner also has sterilization effect.
PROBLEM TO BE SOLVED: To obtain a new compound that has protein dephosphorylation enzyme inhibitory action and is useful as an antineoplastic agent, immunosuppressant, diabetes-therapeutic agent, etc. SOLUTION: This new compound of the formula (R&lt;1&gt; is H, a 1-20C alkyl; R&lt;2&gt; is cyano or acetyl), e.g. 3-cyano-4-methyl-4-vinylidene-2-pyrrolidone, is obtained by treating a compound obtained by condensation of 3,3-dioxobutane and a compound of formula R&lt;2&gt; CH2 CONHR&#39;, with an acid (e.g. camphor-10- sulfonic acid) in a solvent (e.g., methylene chloride), where necessary. The compound of the formula is used without any additional processing or as a preparation prepared by a conventional method in the form of a tablet, pill, capsule, granule, liquid drug, emulsion, suspension, or injection drug. The oral dosage of the compound is 1-1000mg a day for an adult, and parenteral dosage is 0.01-100mg a day, and dosed at a time or by dispensing this quantity to two to several doses.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a moisturizing plant extract with sustainable moisture retaining effect for many hours, an external preparation, a cosmetic, a bathing agent and a detergent composition.  &lt;P&gt;SOLUTION: The moisturizing plant extract comprises an extract of a mixture of Pueraria lobata Ohwi, Paeonia lactiflora Pallas, Glycyrrhiza glabra Linne, Zingiber officinale Roscoe and Cimicifuga simplex Wormskjord. The cosmetic, the bathing agent and the detergent composition each comprises the extract. The product made by decocting a prescribed ratio of the above-mentioned crude medicine has the same composition as that of a medicine which is called Shoumakakkontou in the traditional Chinese medical science and is regarded effective for common cold at initial stage and dermatitis. The extract of the mixture of these crude medicines contains a moisturizing plant component with sustainable moisture retaining effect for many hours and exhibits effects, by external use, on preventing, mitigating or ameliorating dry skin, rough skin, crack, chapped skin, dandruff, itching and inflammatory diseases, and on the hair, in curing dryness, looseness, split hair and broken hair and imparting gloss, and the like.  &lt;P&gt;COPYRIGHT: (C)2007,JPO&amp;INPIT
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a high-safety antiallergic composition that includes an edible plant, butterbur, as a raw material and can be used for prophylaxis and therapy of allergic diseases.  &lt;P&gt;SOLUTION: The antiallergic composition includes an extract of butterbur with a solvent. The raw material for extraction is collected preferably from the on-ground part of the butterbur plant. The extraction solvent is moisture ethanol and desirably the concentration of the ethanol is 40 to 90 % (wt/wt). In a preferred embodiment, the antiallergic composition can be further combined with one kind or two or more kinds of solvent extracts selected from beefsteak plant, lemon balm, sweet tea, Psidium, pollen, black rice, litchee and rose flower.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a therapeutic agent for liver cancer that comprises rifampicin or its derivative as an active ingredient.  &lt;P&gt;SOLUTION: An extensive study was made for the purpose of developing a therapeutic agent for liver cancer. As a consequence, it is found that rifampicin or a derivative thereof has a therapeutic effect on liver cancer, particularly metastatic liver cancer. Rifampicin or a derivative thereof has an action of suppressing the proliferation of cancer metastasized to the liver and the invasion of the cancer into a liver tissue, and has a therapeutic effect on metastatic liver cancer. Rifampicin or a derivative thereof is useful as a therapeutic agent for metastatic liver cancer or an active ingredient of an inhibitor of cancer metastasis to the liver.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
PROBLEM TO BE SOLVED: To obtain a plaster containing an isosorbide dinitrate (hereinafter referred to as ISDN) capable of suppressing the occurrence of skin rash and excellent in pereutaneous absorption and tackiness and having good sustained release property. SOLUTION: This plaster is obtained by forming a tacky composition containing ISDN on a flexible carrier. The tacky composition comprises (A) a silicone based tacky agent of the formula [Me is CH3 or O-Si(Me)3 ; R&#39; is OH or CH3 ; (x) and (y) are each 50-50000], (B) a polyvinyl acetate-based tacky agent and (C) ISDN. The weight ratio of each component is shown as follows. A:B=(85:15) to (15:85); (A+B):C=(90:10) to (60:40). A tacky agent layer of a mixture-based tacky agent not containing ISDN is obtained and a solution containing ISDN is attached to the tacky agent layer and then, the tacky agent layer to which ISDN is attached is heated or aged and ISDN is incorporated into the tacky agent layer to provide a tacky composition. A carrier obtained by laminating a polyester film, an adhesive layer and a polyester fabric is used as the carrier.
The present invention provides a cosmetic system for disguising dermatological blemishes. The cosmetic system includes a viscous silicone material and a catalyst. The silicone material is pigmented with a cosmetic pigment according to a selected skin tone. In one aspect, the cosmetic system also includes a flocking agent. The flocking agent is mixed within the silicone material or the catalyst to provide texture. The cosmetic system also includes at least two cartridges. The cartridges hold the viscous silicone material and the catalyst, separately. Optionally, the cosmetic system includes a dispensing gun. The dispensing gun has a tip through which the silicone material and the catalyst may be dispensed, whereupon the silicone material and the catalyst are mixed and applied to a user&#39;s skin for curing. A method for disguising dermatological blemishes is also provided herein.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a skin care preparation for external use, obtained by formulating black vinegar or an extract of the black vinegar.  &lt;P&gt;SOLUTION: The black vinegar is obtained by fermenting/maturing cereals such as a rice and a wheat for two or more months regardless of the cleaning degree. A longer maturing time is preferable because the longer the maturing period becomes, the more the contents of components such as vitamins, minerals and amino acids are increased. The black vinegar has antiaging activities, bleaching activities, antiinflammatory activities, high humectant activities and antioxidant activities, and the application thereof to the skin care preparation for external use is effective. As a result, the black vinegar is utilizable for a drug, a quasi drug and a cosmetic.  &lt;P&gt;COPYRIGHT: (C)2004,JPO&amp;NCIPI
Compositions including anti-viral compositions, therapeutic compositions, sunscreen compositions, skin treatment compositions, anti-aging compositions, and methods of making the same, are provided. Each composition includes milk fat globules (MFG) and may contain one or more agents encapsulated by the MFG. The unique nature of MFG provides an intact mammalian membrane containing proteins, glycoproteins, and carbohydrates found in mammary cells. By treating an infected patient with MFG, the MFG serve as a surrogate cell and interact with enveloped viruses, such as the COVID-19 coronavirus, the Herpes virus, and the Epstein Barr Virus, rendering them non-infectious. MFG derived from mammals can also be used to deliver pharmaceutical materials into an animal body such that the pharmaceutical materials bypass the venous blood and enter directly into the animal&#39;s lymphatic system. MFG allow the delivery of materials orally that could not heretofore have been delivered efficiently.
The invention relates to a Steroid Receptor RNA Activator (termed SRA) which acts as a steroid hormone receptor coactivator and to the detection of RNA transcripts capable of transactivation of a DNA sequence. The use of SRA to detect protein/RNA interactions including the specific situation of RNA/protein interactions for transactivation of heterologous promoters is described. Methods to evaluate or modulate type I or &#39;classical&#39; nuclear receptors are also described. Furthermore, SRA and its expression levels can facilitate design and evaluation of agents capable of modulating its levels or interactions with other proteins. It also relates to the levels of SRA expression facilitating detection, prognosis or treatment of steroid-dependent tumors or to the detection of prenatal or postnatal cortisol resistance. Finally, SRA expression patterns can be utilized to detect steroid receptor expression patterns.
PURPOSE:A remedy for athlete&#39;s foot, containing cetyltrimethylammonium chloride and fine particulate sulfur as active ingredients and capable of exhibiting remarkable effect on chronic athlete&#39;s foot, particularly even on erosive moist athlete&#39;s foot. CONSTITUTION:A remedy for athlete&#39;s foot obtained by blending 0.1-1%, preferably 0.2-0.8% cetyltrimethylammonium chloride expressed by the formula with 2-10%, preferably 3-6% fine particulate sulfur. Colloidal sulfur obtained by adding hydrochloric acid to calcium sulfate solution to precipitate the sulfur is most suited to the fine particulate sulfur. The dosage form is preferably the form of ointment for moist symptoms and jelly or solution for dry symptoms. A hydrophilic base, e.g. PEG, etc., is preferred for a base of the ointment and further use of propylene glycol together enhance the drug effect.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an antiviral agent which excels in safety, enables daily medication/intake over a long time, and has an antiviral action against pathogenic virus of the cause of infectious diseases of animals including a human.  &lt;P&gt;SOLUTION: The antiviral agent has a pepsin hydrolyzate of lactoferrin as an active ingredient and particularly exhibits an antiviral action against RS virus. The antiviral agent has a peptide described in Sequence No. 1 as an active ingredient, and particularly exhibits an antiviral action against RS virus or influenza virus. A food and a drink or a feed contains the antiviral agent.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
PURPOSE:The titled remedy, obtained by dissolving a composition, containing a carbonate and an organic acid and reacting in water to generate gas bubbles in water and consisting of a solution containing a specific amount or more of carbon dioxide. CONSTITUTION:A remedy for decubitus obtained by containing a carbonate, e.g. NaHCO3, Na3CO3, etc., and an organic acid, e.g. succinc aid, fumaric acid, citric acid, tartaric acid, malic acid, etc., to give a composition, adjusting the pH of a 0.1wt% solution thereof to 4-7, and dissolving the resultant composition reactive in water to generate gas bubbles in water to afford a solution containing &gt;=300ppm carbon dioxide. The amount of the organic acid to be blended varies with the kind of the organic acid. For example, the amount of the succinic acid to be blended is preferably 20-200wt% based on the carbonate (expressed in terms of NaHCO3). 50-250g above-mentioned composition is dissolved in 5-20l water to provide the aimed solution containing CO2 in the above-mentioned concentration. Examples of the dosage form include powder, granule, tablet, etc.
PURPOSE:The titled cosmetic, prepared by dissolving a fatty acid ester of ascorbic acid transparently in an esterification product of a polyether polyol obtained by adding an alkylene oxide to a polyol with a higher fatty acid, and having improved stability. CONSTITUTION:An oily beautifying and whitening cosmetic obtained by dissolving (A) a fatty acid ester of ascorbic acid, e.g. monostearate, transparently in (B) an esterification product of a polyether polyol obtained by adding an alkylene oxide to a polyol, e.g. polyethylene glycol, with a &gt;=8C higher fatty acid, e.g. isooctylic acid. The resultant cosmetic is capable of acting rapidly on and permeating through the skin in use without causing clouding, gelation nor deterioration in the beautifying and whitening effects even on storage for a long term, and giving improved beautifying and whitening effects and good touch to the skin. The amount of the component (A) to be incorporated is 0.1-5wt%. If a liquid oily base material, e.g. olive oil, is incorporated in the cosmetic, the amount of the component (A) is 0.1-3wt%.
Compounds that selectively inhibit the GluN2 subunits of NMDA receptors are disclosed. In general, the compounds have superior activity against GluN2C/D subunit(s) over GluN2A/B subunit(s). Optionally, the compounds have a structure of Formulas (I), (II), (III), or other formulas disclosed herein, enantiomers or diastereomers thereof, or pharmaceutically acceptable salts thereof. Pharmaceutical formulations containing one or more of the compounds are also disclosed. Additionally, methods of treating a neurological condition or disorder using the compounds or their pharmaceutical formulations thereof are disclosed. Exemplary neurological conditions or disorders include Parkinson&#39;s disease, dystonia and related motor disorders, depression, neuropsychiatric indications, stoke, hypoxia, traumatic brain injury, acute injuries involving the white matter, Alzheimer&#39;s disease, compulsivity and related disorders, and epilepsy.
PCT No. PCT/US94/05395 Sec. 371 Date Oct. 27, 1995 Sec. 102(e) Date Oct. 27, 1995 PCT Filed May 19, 1994 PCT Pub. No. WO94/27980 PCT Pub. Date Dec. 8, 1994A class of substituted oxazolyl compounds is described for use in treating inflammation and inflammation-related disorders. Compounds of particular interest are defined by Formula I:    &lt;IMAGE&gt;  I  wherein R is selected from alkyl, hydroxyalkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl optionally substituted at a substitutable position by carboxy, alkyl, alkoxy and halo, aralkyl optionally substituted at a substitutable position on the aryl radical by carboxy, alkyl, alkoxy and halo, aryloxyalkyl optionally substituted at a substitutable position on the aryl radical with halo, carboxy, alkyl and alkoxy, aralkoxyalkyl optionally substituted at a substitutable position by alkyl, carboxy, alkoxy and halo, heteroaryloxyalkyl optionally substituted at a substitutable position with halo, carboxy, alkyl and alkoxy, alkoxycarbonylalkyl, carboxyalkyl and aminocarbonylalkyl; wherein R1 is selected from cycloalkyl, cycloalkenyl, heteroaryl and aryl optionally substituted at a substitutable position by alkyl, alkoxy and halo, and wherein R2 is alkyl; or a pharmaceutically-acceptable salt thereof; provided R1 is not phenyl when R2 is methyl and R is isopropyl or tert-butyl.
The N-demethylation and N,N-demethylation derivatives of the two conformational isomers toluidine blue O (&#34;&#34;TBO&#34;&#34;) have been isolated, identified and prepared. An in vivo biological stain composition includes the conformational isomers of TBO and these N- and N,N-demethylation derivatives. The ratio of these isomers to these demethylation derivatives is at least 6:1. An improved method for detecting displastic oral tissue includes application of such TBO products, in a liquid carrier, to oral tissue. A process for preparing TBO products includes (1) oxidizing N,N-dimethyl-rho-phenylenediamine to form an intermediate 2-amino-5-dimethylaminophenyl thiosulfonic acid, (2) oxidizing this intermediate and condensing the oxidizate with o-toluidine, forming indamine thiosulfonic acid and (3) further oxidizing the indamine intermediate to form a TBO-containing reaction product, which is precipitated from the reaction mixture as a complex, from which the final TBO product is separated. The complexing agent is added to the reaction mixture at least before the final oxidation stop, preferably before the second oxidation step. An HPLC method for characterizing TBO products containing the conformational isomers of TBO and their N- and N,N-demethylation derivatives. The a mobile phase comprises an aqueous solution of an organic acid compound.
The present invention is a system and method for facilitating the process of caring for an individual, such as an elder. The present invention also disseminates a wide range of information to users. The system allows members of an elder&#39;s support group to easily and conveniently communicate and coordinate their actions. The present invention is accomplished by the creation of an “e-space” for the elder. The e-space is a set of data files that are associated with the elder. The e-space is stored in a central location that can be accessed conveniently by individuals by accessing a computer network such as the Internet. The system also allows the elder (or an agent of the elder called a “responsible party”) to maintain his or her privacy by controlling access to his or her e-space. This is accomplished by providing the elder or responsible party the ability to specify varying levels of access privileges for each type of data file in his/her e-space for each member of his/her support group. The system also allows the elder to delegate privileging power to an administrator or official at the care provider facility where he or she is residing. The administrator/official can then grant access privileges to members of the care provider staff The system also provides a variety of information and tools which assist individuals in making decisions related to elder care.
PURPOSE:To obtain a new nucleotide useful for curing and preventing AIDS diseases and having excellent antiviral activities, especially a specific inhibiting activity against an AIDS virus (HIV-1) and specifically inhibiting their proliferation. CONSTITUTION:A new compound is expressed by the formula [(n) is 1-7, preferably an integer; B is independently a nucleic acid base in each nucleic acid unit. X is independently S and O atom, preferably all Xs are S; Here, at least one of Xs is S] or its salt. Here, as for a base arrangement of the compound of the formula I, the one which has guanine (G) at the fourth position from the 5&#39; end is preferable. More preferable arrangements are a group of TGGGAG (T is thymine; A is adenine). CGGGAGG (C is cytosine), etc. Specifically preferable arrangements are expressed by a group of TGGGAG, TGGGA, etc. E.g. AATGGGAGG, etc. The compound of the formula can be obtained by the photosphorodiamide method.
The invention discloses a Jin&#39;gui Juanbi pill for treating arthralgia and a preparation method thereof. The pill comprises a main material and an auxiliary material; wherein the main material is composed of following traditional Chinese medicine decoction pieces of radix rehmanniae preparata, Chinese angelica, ground beetle, spatholobus stem, leech, and achyranthes root, and the auxiliary material is composed of honey, wheat flour, and drinking water. The preparation method comprises the following steps: preparing raw materials, grinding, drying through baking, evenly mixing, heating the materials in a boiler, maintaining the temperature to carry out fermentation, neutralizing the pharmaceutical properties, granulating to produce particles with a size of 6 millimeters or so by hands or a pilling machine, and finally drying through baking or in the air to obtain the Jin&#39;gui Juanbi pill. The pill is orally taken along with warm boiled water after meals, three times a day, 30 pills with a weight of 4 grams or so are taken for each time, one treatment course lasts for 60 days, and the arthralgia can be cured within 1-4 treatment courses. The Jin&#39;gui Juanbi pill has the advantages of dispelling wind, removing dampness, exciting the nerves, tonifying essence, boosting marrow, freeing collaterals, relieving pains, activating blood circulation to remove blood stasis, and softening the bone spur, and is suitable for treating arthralgia patients. In clinic, the Jin&#39;gui Juanbi pill has been applied to 48 patients for 1 to 3 treatment courses, 8 patients (17%) have been cured, the pill is effective for 12 patients (25%), the symptoms of 25 patients (52%) have been relieved, the pill is ineffective to 3 patients (6%), and the total effective rate is 94%.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide service for securely recording living body information of an outpatient and performing precise medical treatment.  &lt;P&gt;SOLUTION: A service system is provided with a server, a client, an IC card into which individual information of the patient is written and a medical treatment terminal used for permitting the patient to measure self-living body information and to transmit it to the server. The medical treatment terminal reads individual information of the patient from the IC card, measures living body information of the patient, works measured living body information into that expressed by a chart, a character and the like, transmits measured living body information, worked living body information and individual information of the patient and writes measured living body information and processed living body information into the IC card. The sever receives individual information of the patient, measured living body information and worked living body information and records them by the individual patients and urges the patient who does not transmit information as a decided schedule to transmit them. The client is used for accessing measured or worked living body information recorded in the server.  &lt;P&gt;COPYRIGHT: (C)2004,JPO